Edwards Lifesciences announce promising new transcatheter patient data

Published date : 02 February 2012
Article date : 02 February 2012

Patient data from a recent clinical trial shows reduced mortality rates in high-risk surgical patients with severe aortic stenosis. The patients were treated with transapical transcatheter transapical transcatheter aortic valve replacement (TAVR) during the continued access period of Cohort A of The PARTNER Trial, 

The findings on the Edwards SAPIEN transcatheter heart valve were announced this week, and Michael A. Mussallem, Edwards Lifesciences' chairman and CEO said "It is encouraging that, in this much larger group of patients treated with transapical valve replacement, investigators observed a trend toward patients feeling better faster and having improved outcomes. We believe this more recent experience adds strong new support to the transapical procedure as an important option for patients who are at high-risk for surgery."

Read the full press release from Edwards Lifesciences here

Find out more about the SAPIEN Transcatheter Heart Valve here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.